{"id":479841,"date":"2021-04-21T16:09:41","date_gmt":"2021-04-21T20:09:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/"},"modified":"2021-04-21T16:09:41","modified_gmt":"2021-04-21T20:09:41","slug":"ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/","title":{"rendered":"Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">COPENHAGEN, Denmark, April  21, 2021  (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations featuring TransCon hGH (lonapegsomatropin) at two upcoming medical conferences: Pediatric Endocrinology Nursing Society (PENS) national conference, taking place virtually April 21-23, and the Pediatric Endocrine Society (PES) annual meeting, taking place virtually April 30 \u2013 May 3, 2021.<\/p>\n<p>\u201cWe look forward to presenting the latest data on lonapegsomatropin, our investigational once-weekly growth hormone, at PENS and PES, two of the leading medical conferences focused on pediatric endocrinology,\u201d said Mark Bach, M.D., Ph.D., Senior Vice President of Endocrine Medical Sciences at Ascendis Pharma.<\/p>\n<p>\u201cWe will present the two-year follow-up data for lonapegsomatropin which show durable results in children treated for pediatric growth hormone deficiency (GHD). In addition, we will present a model which can estimate the average weekly insulin-like growth factor 1 (IGF-1) level from a single IGF-1 sample in children with GHD treated with lonapegsomatropin. This tool may help physicians effectively manage patients on lonapegsomatropin therapy following regulatory approval,\u201d continued Dr. Bach.<\/p>\n<p>\n        <strong>2021 PENS Virtual National Conference: Presentation Details<\/strong>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>Poster Presentation<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:75%;width:75%;min-width:75%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Title<\/strong>\n          <\/td>\n<td style=\"max-width:25%;width:25%;min-width:25%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Date\/Time<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Continued Efficacy and Safety with up to 2 Years of Treatment with Lonapegsomatropin (TransCon hGH) in Children with GHD.<\/p>\n<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Number: 6<br \/>Poster Session<br \/>April 23, 2021<br \/>1:30 \u2013 2:00 p.m. Eastern Time<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>2021 PES Virtual Annual Meeting: Presentation Details<\/strong>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>Poster Presentations<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:75%;width:75%;min-width:75%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Title<\/strong>\n          <\/td>\n<td style=\"max-width:25%;width:25%;min-width:25%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Date\/Time<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Lonapegsomatropin (TransCon hGH) in Children with Growth Hormone Deficiency: Efficacy and Safety of up to 2 Years of Treatment.<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Number: 154<br \/>Poster 2 Viewing Session: Growth and GH\/IGF Axis<br \/>May 1, 2021<br \/>5:45- 6:45 p.m. Eastern Time<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Estimating the weekly average IGF-1 from a single IGF-1 sample for children with GHD treated with lonapegsomatropin.<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Number: 156<br \/>Poster 2 Viewing Session: Growth and GH\/IGF Axis<br \/>May 1, 2021<br \/>5:45- 6:45 p.m. Eastern Time <\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>The posters will be available on the Ascendis website under Selected Publications in the Pipeline section: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=saTRBYIWWOtKK_3W8nv9VdfOvt0Sk1o5DwB8tkAvZK8INoZWOY39gWoQvEKRwoFpst_lCCHXZM2DzNLhJcuHkbbfVEOSMI324mt7uQ8DRyEYo2gpXllun1LoLIaLnVISh9KsHBliOdmXy59z-u2DxFeGxUKKk0IGVS4R-5AjqWk=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ascendispharma.us\/pipeline\/publications\/<\/a>. If you are a healthcare provider who would like more information, please contact: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RFg3RlN25ND0XYikC3rH4JCO5dTeTzRDbooVH9mROqVbkfFpTdKvQ1mblGmIa_SKmKPoSrhqm6V-Bvp-re5eq9EW2EyBDyYAbqNQfyc8FTUjyhDoDPqBkpHxIKtVSgFD\" rel=\"nofollow noopener\" target=\"_blank\">medicalaffairs@ascendispharma.com<\/a>.<\/p>\n<p>\n        <strong>About TransCon\u2122 Technology<\/strong>\n      <\/p>\n<p>TransCon refers to \u201ctransient conjugation.\u201d The proprietary TransCon platform is an innovative technology to create new therapies that are designed to optimize therapeutic effect, including efficacy, safety and dosing frequency. TransCon molecules have three components: an unmodified parent drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from clearance. When injected into the body, physiologic conditions (e.g., pH and temperature) initiate the release of the active, unmodified parent drug in a predictable manner. Because the parent drug is unmodified, its original mode of action is expected to be maintained. TransCon technology can be applied broadly to a protein, peptide or small molecule in multiple therapeutic areas, and can be used systemically or locally.<\/p>\n<p>\n        <strong>About\u00a0Ascendis Pharma A\/S\u00a0<\/strong>\n      <\/p>\n<p>Ascendis Pharma\u00a0is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients\u2019 lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.<\/p>\n<p>Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates and one oncology product candidate in clinical development. The company continues to expand into additional therapeutic areas to address unmet patient needs.<\/p>\n<p>Ascendis is headquartered in\u00a0Copenhagen, Denmark, with additional offices in Heidelberg and\u00a0Berlin, Germany, in\u00a0Palo Alto\u00a0and\u00a0Redwood City, California, and in Princeton, New Jersey.<\/p>\n<p>Please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RySX7_wD_2hXC717dXJTdY95b4O8qLHMail2roaPumuNoplb04gQJ8r4BQbI2iY8yeLtawQ4GuftQS7LHUUDknQhkwQNEJi3SXy3zOHyGqQ=\" rel=\"nofollow noopener\" target=\"_blank\">www.ascendispharma.com<\/a> (for global information) or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RySX7_wD_2hXC717dXJTdcsJuihcdcWU0S8VMJEldoXQvo5L-ALIi_a2GHApyDqjO9FZ3aWG1_5YoDDWoYrq1Y1h7PS8qU6JAZBBpHwXxsY=\" rel=\"nofollow noopener\" target=\"_blank\">www.ascendispharma.us<\/a> (for U.S. information).<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis\u2019 future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis\u2019 plans to present follow-up data for lonapegsomatropin and a model to estimate the weekly average IGF-1 level from a single IGF-1 sample in children with GHD treated with lonapegsomatropin, (ii) Ascendis\u2019 ability to apply its platform technology to build a leading, fully integrated biopharmaceutical company, (iii) Ascendis\u2019 product pipeline and expansion into additional therapeutic areas and (iv) Ascendis\u2019 expectations regarding its ability to utilize its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: unforeseen safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis\u2019 business generally; delays in the development of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis\u2019 ability to obtain additional funding, if needed, to support its business activities and the effects on its business from the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis\u2019 business in general, see Ascendis\u2019 Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 10, 2021 and Ascendis\u2019 other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.<\/p>\n<p>\n        <em>Ascendis,\u00a0Ascendis Pharma, the\u00a0Ascendis Pharma\u00a0logo, the company logo and TransCon are trademarks owned by the\u00a0Ascendis Pharma Group. \u00a9\u00a0April 2021\u00a0Ascendis Pharma A\/S.<\/em>\n      <\/p>\n<table style=\"border-collapse: collapse;width:50%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:51%;width:51%;min-width:51%\">\n            <strong><br \/>\n              <u>Investor contacts:<\/u><br \/>\n            <\/strong>\n          <\/td>\n<td style=\"max-width:49%;width:49%;min-width:49%\">\n            <strong><br \/>\n              <u>Media contact:<\/u><br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Tim Lee<\/td>\n<td>Ami Knoefler<\/td>\n<\/tr>\n<tr>\n<td>Ascendis Pharma<\/td>\n<td>Ascendis Pharma<\/td>\n<\/tr>\n<tr>\n<td>(650) 374-6343<\/td>\n<td>(650) 739-9952<\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:tle@ascendispharma.com\" rel=\"nofollow noopener\" target=\"_blank\">tle@ascendispharma.com<\/a>\n          <\/td>\n<td>\n            <a href=\"mailto:ack@ascendispharma.com\" rel=\"nofollow noopener\" target=\"_blank\">ack@ascendispharma.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Patti Bank<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Westwicke Partners<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>(415) 513-1284<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:patti.bank@westwicke.com\" rel=\"nofollow noopener\" target=\"_blank\">patti.bank@westwicke.com<\/a>\n          <\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:ir@ascendispharma.com\" rel=\"nofollow noopener\" target=\"_blank\">ir@ascendispharma.com<\/a>\n          <\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMTM3MCM0MTMyOTg2IzIwMTEyMzQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/596ed51d-5580-432b-ace9-c7860948345b\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations featuring TransCon hGH (lonapegsomatropin) at two upcoming medical conferences: Pediatric Endocrinology Nursing Society (PENS) national conference, taking place virtually April 21-23, and the Pediatric Endocrine Society (PES) annual meeting, taking place virtually April 30 \u2013 May 3, 2021. \u201cWe look forward to presenting the latest data on lonapegsomatropin, our investigational once-weekly growth hormone, at PENS and PES, two of the leading medical conferences focused on pediatric endocrinology,\u201d said Mark Bach, M.D., Ph.D., Senior Vice President of Endocrine Medical Sciences at Ascendis Pharma. \u201cWe will present the two-year follow-up data for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-479841","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations featuring TransCon hGH (lonapegsomatropin) at two upcoming medical conferences: Pediatric Endocrinology Nursing Society (PENS) national conference, taking place virtually April 21-23, and the Pediatric Endocrine Society (PES) annual meeting, taking place virtually April 30 \u2013 May 3, 2021. \u201cWe look forward to presenting the latest data on lonapegsomatropin, our investigational once-weekly growth hormone, at PENS and PES, two of the leading medical conferences focused on pediatric endocrinology,\u201d said Mark Bach, M.D., Ph.D., Senior Vice President of Endocrine Medical Sciences at Ascendis Pharma. \u201cWe will present the two-year follow-up data for &hellip; Continue reading &quot;Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-21T20:09:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMTM3MCM0MTMyOTg2IzIwMTEyMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ascendis Pharma A\\\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences\",\"datePublished\":\"2021-04-21T20:09:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/\"},\"wordCount\":1098,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMTM3MCM0MTMyOTg2IzIwMTEyMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/\",\"name\":\"Ascendis Pharma A\\\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMTM3MCM0MTMyOTg2IzIwMTEyMzQ=\",\"datePublished\":\"2021-04-21T20:09:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMTM3MCM0MTMyOTg2IzIwMTEyMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMTM3MCM0MTMyOTg2IzIwMTEyMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascendis Pharma A\\\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences - Market Newsdesk","og_description":"COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations featuring TransCon hGH (lonapegsomatropin) at two upcoming medical conferences: Pediatric Endocrinology Nursing Society (PENS) national conference, taking place virtually April 21-23, and the Pediatric Endocrine Society (PES) annual meeting, taking place virtually April 30 \u2013 May 3, 2021. \u201cWe look forward to presenting the latest data on lonapegsomatropin, our investigational once-weekly growth hormone, at PENS and PES, two of the leading medical conferences focused on pediatric endocrinology,\u201d said Mark Bach, M.D., Ph.D., Senior Vice President of Endocrine Medical Sciences at Ascendis Pharma. \u201cWe will present the two-year follow-up data for &hellip; Continue reading \"Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-21T20:09:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMTM3MCM0MTMyOTg2IzIwMTEyMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences","datePublished":"2021-04-21T20:09:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/"},"wordCount":1098,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMTM3MCM0MTMyOTg2IzIwMTEyMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/","name":"Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMTM3MCM0MTMyOTg2IzIwMTEyMzQ=","datePublished":"2021-04-21T20:09:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMTM3MCM0MTMyOTg2IzIwMTEyMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMTM3MCM0MTMyOTg2IzIwMTEyMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-presentations-for-transcon-hgh-at-upcoming-medical-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 hGH at Upcoming Medical Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=479841"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479841\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=479841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=479841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=479841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}